The Foundation in the News
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
-
Jan 29, 2021 The Foundation in the News
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
-
Dec 16, 2020 The Foundation in the News
-
Dec 14, 2020 The Foundation in the News
End Blindness 2020 Award Winners include Five Foundation-Funded Investigators
All News Stories
-
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board
Development of lead asset SPVN06 to further benefit from high-level Clinical Advisory Board
-
Round was led by Sofinnova Investments with participation from Abingworth, Lightstone Ventures and all existing investors.
Company expands board of directors and plans to build out team.
-
End Blindness 2020 Award Winners include Five Foundation-Funded Investigators
Live stream ceremony will include Art Garfunkel, Diane Schuur, and Margaret Atwood. A tribute will also be made to Justice Ruth Bader Ginsburg.
-
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
The Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Foundation Fighting Blindness and the Retinal Degeneration Fund
In 2018, the Foundation Fighting Blindness launched a venture philanthropy investment arm called the Retinal Degeneration (RD) Fund to help companies and researchers advance promising treatments for inherited retinal diseases into and through early-stage human studies. Currently, the RD Fund has allocated about 75% of its $72 million fund to eight investments.
-
Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the Foundation Fighting Blindness
